March 13, 2024Open Access

Patented Medicines Expenditure in Canada 1990–2022 8TH Edition

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

OPEN ACCESS Patented Medicines Expenditure in Canada 1990–2022 8TH Edition ATTRIBUTION This legacy paper is corporately authored and edited based on proprietary template models and methods that are intended to facilitate regular updates. The design and content are

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Brett Skinner (Wed,) studied this question.

synapsesocial.com/papers/68e7445fb6db6435876bdd53 https://doi.org/https://doi.org/10.54194/ryjn9568

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Public v private insurance coverage for new drugs in Canada, 2018-2023, 7th EditionPublic v private insurance coverage for new drugs in Canada, 2018-2023, 7th Edition2024 · 1 citations
2International patented medicine prices: how does Canada compare to the OECD? A descriptive analysis of list prices2026
3“Breakthrough” drugs and growth in expenditure on prescription drugs in Canada2005 · 107 citations
4Waiting for new medicines in Canada, Europe, and the United States2024 · 1 citations
5The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study2024 · 4 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo